KLOW vs GLOW: What 10 mg of KPV Changes (2026 Lab Data)

KLOW is GLOW plus one ingredient, and that ingredient has never been tested in a human study.

The ingredient is KPV, and it takes up one-eighth of the vial. The copper peptide, BPC-157, TB-500 and their ratio are identical in both.

So the useful questions are narrower than “which is better?” Does your research need what KPV did in a mouse’s gut? And does the vial hold what the label says?

Status as of October 2026: neither blend is FDA approved, and both are sold for laboratory research use only. Nothing here explains how to use either one.

Jump to: The difference · What KPV adds · Tested? · The sting · Which is better · Lab reports · Safety · FDA status · Price · Who should skip both · FAQ

What is the difference between KLOW and GLOW?

KPV is the only difference.

Some sellers bend the formula. One sells a 65 mg KLOW with half the BPC-157, TB-500 and KPV, so read the label before you compare prices.

KPV is three amino acids: lysine, proline and valine. It’s the tail end of α-MSH, a hormone your body already makes. In lab and animal studies, it keeps that hormone’s anti-inflammatory signal and drops the tanning effect.

GLOW came first. Reddit posts about it appear from spring 2025, and the earliest dated KLOW product page we found was archived in June 2025. Sellers now pitch KLOW as the upgrade, which only matters if you need what KPV does.

What does KPV add?

In mice, KPV calmed gut inflammation. In people, nobody has measured anything.

The FDA reviewed KPV in May 2026. It wrote that it “did not identify data, such as clinical studies, on the use of KPV in humans.”

The mice got KPV by mouth, in drinking water or in particles built to reach the colon. It enters gut cells through a transporter called PepT1, and inflamed colons make more of it.

KLOW isn’t a pill. Nobody has measured whether KPV from a vial ever reaches the gut lining.

That makes KPV a gut and inflammation bet with no human data behind it. If gut or inflammation isn’t the research question, GLOW already holds every other milligram.

Has anyone tested GLOW or KLOW?

No. We searched PubMed and ClinicalTrials.gov in October 2026 and found zero studies of either blend. We also found zero studies pairing GHK-Cu or KPV with BPC-157 or TB-500.

The closest data covers just two of the ingredients:

• A 2026 rat study gave BPC-157, TB-500 or both to rats after Achilles tendon surgery. The pair “did not confer additional benefits compared to either agent alone.” Evidence grade: animal.
• A 2021 knee chart review included 4 people given BPC-157 plus thymosin beta-4. Three said their pain improved. There was no control group, only a phone survey. Evidence grade: human, tiny, uncontrolled.
• One FDA adverse event report describes a woman who used a “research purposes only” BPC-157 and TB-500 product. Her skin and gums darkened, and it happened again when she used it again. A second report describes redness and swelling that lasted 9 days after BPC-157 was used with thymosin.

Three dental case reports also mixed these peptides with other drugs, and their authors wrote that “causality cannot be established.” That’s the published record we found.

The FDA found KPV marketed with BPC-157 and TB-500 as a “regenerative combo,” yet the only test of a two-peptide combo found no added benefit.

Does KLOW sting less than GLOW?

Nobody has tested it, though it’s the question people ask most.

GHK-Cu is known for a burning welt, and that burn drives a lot of KLOW vs GLOW talk. One Reddit user summed up the belief in May 2026: “Klow, less sting. Does more.” Another, in r/Peptides that same month, reported the opposite: “KLOW can leave a welt for many hours.”

The Reddit user credited with the original GHK-Cu to BPC-157 formula says it was written to prevent the sting. If that’s true, the anti-sting ingredient was BPC-157, and BPC-157 is in both vials.

So paying extra for KLOW only to avoid the burn means paying for a hunch. Community reports point both ways, and no study has checked.

Which is better: KLOW or GLOW?

It depends on the research goal.

A July 2026 Reddit thread titled “GLP1 face – will KLOW fix?” drew 130 comments. In a similar r/Peptides thread that August, a top-voted reply read: “This won’t work. Don’t waste your money. Save up for a procedure.” That’s one person’s view, and no study contradicts it.

What do KLOW and GLOW lab reports show?

None of the KLOW reports we opened was missing KPV.

We read 19 KLOW lot reports from third-party labs. KPV ran from 87% to 134% of its label, and overfill was more common than underfill. One vial labeled 80 mg measured 101 mg.

All values are milligrams measured per vial. Ameano and EZ Peptides posted identical results for the same batches, so count them as one source.

The label word “TB-500” covers more than one molecule. The FDA defines TB-500 as a 7-amino-acid fragment of thymosin beta-4, but most blend reports we read measured the full 43-amino-acid protein. One GLOW report read “TB-500 (889 Da),” which is the fragment. A KLOW report read “TB-4 (1-4),” which matches neither form. Each molecule has its own research behind it.

A blend report has two more limits:

• One purity number tells you nothing about each peptide. On one report, KPV made up 0.06% of the peak area yet measured 13.37 mg. Ask for milligrams of each peptide, not a single “99.8%.”
• Blue only shows that copper is there. A colorless vial means little or no copper. One user’s lab test of a GLOW vial found 29.8 mg GHK-Cu, 19.6 mg BPC-157, 7.9 mg TB-500 and 18% impurities, none of which color would reveal.

Our guide on how to read a peptide COA covers the rest.

Is KLOW or GLOW safe? Cancer, copper and side effects

Nobody can say, because nobody has run a safety study on either blend.

Cancer risk

BPC-157, thymosin beta-4 and GHK-Cu all spur new blood vessel growth in lab and animal studies. Tumors need new blood vessels too. In mice, extra thymosin beta-4 helped melanoma spread.

Our search of PubMed and FDA records found no human cancer case linked to any of the four peptides. The risk is theoretical, and nobody has ruled it out. The FDA notes that BPC-157 has never had a carcinogenicity study, the long-term test for cancer risk.

Copper load

50 mg of GHK-Cu holds about 7.9 mg of elemental copper. That’s roughly 9 times the adult daily need of 0.9 mg, in one vial.

Daily limits are set for food, and copper from a vial skips the gut’s own controls. Some Janoshik reports list copper separately, and one KLOW vial held 7.18 mg. Most other seller reports we read don’t list it.

What users report

These reports are anecdotes that nobody measured. People describe the sting and welts, breakouts they call “copper uglies,” poor sleep and fatigue. Some on GLP-1s report more hunger, and some report dizziness they blame on KPV.

One Reddit user wrote in May 2026, “I have a reaction to KPV.” Reports like that are one reason some buyers pick GLOW, which has none.

Contamination

Sellers choose which samples go to the lab. Among the sellers we reviewed, only Amino Club, Ameano and EZ Peptides (one source), Ascension, Licensed Peptides and Platinum publish endotoxin results for these blends. Before you buy, ask for the endotoxin and sterility results on the same lot number as the vial.

Are KLOW and GLOW FDA approved?

No. As of October 2026, the record looks like this:

WADA’s 2026 list bans BPC-157 and “thymosin-β4 and its derivatives e.g. TB-500.” Both blends contain both, so either one can end the season of anyone who competes in a tested sport.

How much more does KLOW cost than GLOW?

$10 to $30 a vial at the same seller, based on prices checked 25 October 2026:

If you want one seller to start with, ours is Amino Club. ILS Laboratories, an ISO 17025 lab, tested its KLOW lot KLW0002 on 30 July 2026. The report measured all four peptides at 52.5, 10.4, 10.6 and 10.3 mg, and screened for sterility, endotoxin, heavy metals and fentanyl. No other report in our set included a fentanyl screen. Amino Club posts every lot’s certificate publicly, so you can read it before you buy.

Don’t shop by price per milligram. GHK-Cu is the cheapest ingredient and 62 to 71% of the mass, so a low price per milligram mostly buys copper peptide. Compare the price against a lab report that measures every peptide in the vial.

Who should skip KLOW and GLOW?

• Anyone under 18
• Anyone tested in sport
• Anyone pregnant or breastfeeding
• Anyone with a current or past cancer
• Anyone with Wilson disease or another copper disorder

What we know and what we don’t

We know the blends differ by 10 mg of KPV, and neither has been studied as a blend. KPV has no human data, and most lab reports show total vial contents at or above the label.

We don’t know whether KPV from a vial reaches the gut or whether it changes the sting. We also don’t know whether the peptides affect each other inside one vial, or which TB-500 molecule a given seller ships.

A controlled human study of KPV, or of either blend, would change our view. We’ll update this page when one appears.

KLOW vs GLOW FAQ

Where to go next

Start with the list of peptide scams to avoid and our guide on how to read a peptide COA. For the blend itself, see our KLOW peptide guide. If injury research is the goal, the Wolverine stack evidence is the shorter read.

Ten milligrams separate these blends. Let the lab report break the tie.

Sources

1. FDA. Briefing document: KPV-related bulk drug substances. May 2026.
2. FDA. Briefing document: TB-500-related bulk drug substances. May 2026.
3. FDA. Briefing document: BPC-157-related bulk drug substances. 2026.
4. FDA. Bulk drug substances that may present significant safety risks. Updated 22 April 2026.
5. Healio. FDA committee recommends looser restrictions for several peptides. 24 July 2026.
6. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
7. Laroui H, et al. Drug-loaded nanoparticles targeted to the colon. Gastroenterology. 2010.
8. Bonfiglio V, et al. α-MSH(11-13) and corneal wound healing in rabbits. Exp Eye Res. 2006.
9. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Jt Dis Relat Surg. 2026.
10. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021.
11. Cha HJ, et al. Role of thymosin β4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003.
12. Esposito S, et al. Ac-LKKTETQ identified in TB-500. Drug Test Anal. 2012.
13. NIH Office of Dietary Supplements. Copper fact sheet for health professionals.
14. WADA. 2026 Prohibited List.
15. Froum S, et al. Regenerative peptides for inferior alveolar nerve injury. Front Oral Health. 2026.